Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. increased its holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 1.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,363,046 shares of the biotechnology company’s stock after purchasing an additional 33,482 shares during the quarter. Vanguard Group Inc. owned 4.75% of Aclaris Therapeutics worth $23,037,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Wellington Management Group LLP raised its holdings in shares of Aclaris Therapeutics by 3.4% during the first quarter. Wellington Management Group LLP now owns 5,730,253 shares of the biotechnology company’s stock valued at $98,789,000 after acquiring an additional 190,985 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Aclaris Therapeutics by 9.4% during the second quarter. BlackRock Inc. now owns 5,594,173 shares of the biotechnology company’s stock valued at $58,012,000 after acquiring an additional 478,800 shares during the last quarter. Braidwell LP raised its holdings in shares of Aclaris Therapeutics by 36.6% during the first quarter. Braidwell LP now owns 3,269,094 shares of the biotechnology company’s stock valued at $26,447,000 after acquiring an additional 875,109 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Aclaris Therapeutics by 29.1% during the second quarter. Point72 Asset Management L.P. now owns 1,736,500 shares of the biotechnology company’s stock valued at $18,008,000 after acquiring an additional 391,900 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Aclaris Therapeutics by 2.0% during the second quarter. State Street Corp now owns 1,451,984 shares of the biotechnology company’s stock valued at $15,057,000 after acquiring an additional 28,630 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the company. HC Wainwright cut Aclaris Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, January 22nd. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a report on Friday, January 12th. BTIG Research reaffirmed a “neutral” rating on shares of Aclaris Therapeutics in a report on Thursday, January 11th. Finally, StockNews.com cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, April 2nd. One analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $22.25.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock opened at $1.21 on Friday. The firm has a market capitalization of $85.83 million, a price-to-earnings ratio of -0.95 and a beta of 0.22. Aclaris Therapeutics, Inc. has a fifty-two week low of $0.59 and a fifty-two week high of $11.12. The stock has a 50 day moving average of $1.21 and a 200 day moving average of $2.12.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. The company had revenue of $17.57 million during the quarter, compared to analyst estimates of $3.96 million. Aclaris Therapeutics had a negative return on equity of 64.56% and a negative net margin of 283.15%. Analysts forecast that Aclaris Therapeutics, Inc. will post -0.98 EPS for the current year.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.